BACKGROUND
Neoadjuvant chemoimmunotherapy (NCIT) is increasingly used for locally advanced esophageal squamous cell carcinoma (ESCC), but the role of adjuvant therapy-particularly immunotherapy-after NCIT remains undefined.
METHODS
This single-institution retrospective study included 458 ESCC patients treated with ne...
Yu-Hao Peng, Xin Xiao, Pin-Hao Fang et al.· European Journal of Surgical...· 0 citations
While delayed surgery after neoadjuvant therapy in esophageal carcinoma patients may be associated with a higher risk of anastomotic leaks and a lower rate of R0 resection, its impact on long-term survival remains an area of ongoing investigation.
Jian-Feng Zhou, Pin-Hao Fang, Yong Yuan et al.· Diseases of the esophagus· 0 citations
Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies
The integration of anti-PD-1 antibody therapy with chemotherapy has shown promising results in the neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma. Conventional imaging may not fully capture immunotherapy effects due to unc...
Jian-Feng Zhou, Yu-Shang Yang, Yong Yuan et al.· Diseases of the esophagus· 0 citations
The TME in residual ESCC after nICT is characterized and revealed an association between elevated TFAM expression in DCs and poor responsiveness to nICT, indicating the critical role of TFAM deficiency in DCs in activating anti-tumor immunity.
Linyan Chen, Tang Feng, Jian-Feng Zhou et al.· Cancer Research· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.